Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Home

Marketplace
Database
News
Store
Resources
Contact Us

 

 

News


VENTURE CAPITAL DIRECTORY | PRIVATE EQUITY DIRECTORY

List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory

2021 EDITION SPECIAL OFFER!
Buy Now for only $119.95 plus a FREE update in January 2022

Learn More or Buy Now

VCPro Database 2021 24th Edition -- a downloadable and searchable venture capital database with 6,500+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. (Updated JULY 2021)

Learn More » or Buy Now »




Inocucor Technologies Closes Extended Series A Financing at $6 Million

Investments from Cycle Capital Management, Desjardins Innovatech, Red Metal Capital, Closed Loop Capital and board members will fund commercial scale-up of Inocucor's sustainable accelerators for sales and new field trials.

MONTREAL, June 1, 2016-- Inocucor Technologies Inc. (www.inocucor.com), the Montreal-based developer of sustainable microbial crop accelerators, announced it has raised an additional $6 million in an extended Series A financing with participation from two Canadian and two U.S.-based early-stage venture capital/family office investors and from board members.

Cycle Capital Management (www.cyclecapital.com), a Montreal Cleantech venture capital fund and early investor in Inocucor, was joined in the funding by Desjardins Innovatech (www.desjardins.com), Canada's leading cooperative financial group with more than $200 billion in assets; Red Metal Capital (www.dormangroupofcompanies.com), a Michigan-based family office fund; and Closed Loop Capital (www.closedloopcapital.com), an early-stage agriculture technology and food system innovation fund based in greater Philadelphia.

The investment will finance the commercial scale-up of Inocucor's patented first-in-class bio-stimulant product, Garden Solution®, which is produced through fermentation akin to winemaking. Inocucor's patented technology enables it to isolate and combine multiple strains of naturally occurring yeasts and bacteria into powerful bio-stimulants that increase the microbial diversity of soils and speed delivery of nutrients to plants, thereby improving crop yields.

"Our business model calls for a range of bio-based products that ultimately will help farmers feed a growing population with fewer or no chemical inputs," said Donald R. Marvin, president and CEO of Inocucor.

Marvin said Inocucor's growth strategy is focused on establishing commercial partnerships that include its intellectual property as a key ingredient for new bio-stimulation, bio-fertility and bio-protection products for large-scale production farmers. It also plans to make strategic acquisitions that will hasten the commercialization of its proprietary microbial consortia technology and broaden its product pipeline.

Garden Solution, OMRI Listed® for organic production, is approved for sale in 27 U.S. states. It is currently in use by farmers and greenhouse growers in North Carolina, South Carolina, Florida, Georgia and Virginia. Marvin said Garden Solution's full registration in California, one of the world's largest agricultural economies, is imminent.

Recent field trials employing Inocucor's first- and second-generation sustainable biological accelerators with leading industry and academic partners in Canada and the U.S. have produced significant yield increases in high-value produce and row crops.

In June, the company will launch a follow-on equity financing round to support opening a U.S. office to better serve its commercial partners and customers. Inocucor will also expand large-scale field trials and commercialization activities in North and South America for its second- and third-generation cell-free biological formulations for bio-stimulation, proprietary new biological entities and active compounds for bio-fertility and bio-protection.

Contact:
Michele Wells, Wells Communications, 303-417-0696
mwells@wellscommunications.net


News Index

Venture Capital Database 

 

 NEWS

Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Business Plan Tools

Free Business Plan Template

 

Copyright © 1998-2021 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer